Stock Forecast

  Fennec Pharmaceuticals Inc. ( FENC) Stock. Should you Buy or Sell?    $ 6.34

-0.54 (-9.31 %)



Fennec Pharmaceuticals Inc. Analysis

Updated on 10-09-2022
Symbol FENC
Price $6.34
Beta 0.090
Volume Avg. $47 thousand
Market Cap $164.96 M
52 Week Range $3.822 - $10.078


Fennec Pharmaceuticals Inc. opened the day at $6.34 which is -9.31 % on yesterday's close. Fennec Pharmaceuticals Inc. has a 52 week high of $10.078 and 52 week low of $3.822, which is a difference of $6.256. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $164.96 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Fennec Pharmaceuticals Inc. for $164.96 M, it would take 15 years to get your money back. Fennec Pharmaceuticals Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Fennec Pharmaceuticals Inc. Stock Forecast - Is Fennec Pharmaceuticals Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreStrong Sell
DE ScoreBuy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -5.451
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Fennec Pharmaceuticals Inc.


Price Book Value Ratio 19.338 Price To Book Ratio 19.338
Price To Sales Ratio 0.000 Price Earnings Ratio -5.451


How liquid is Fennec Pharmaceuticals Inc.


Current Ratio 5.122
Quick Ratio 4.911


Debt


Debt Ratio 0.451 Debt Equity Ratio 0.823
Long Term Debt To Capitalization 0.318 Total Debt To Capitalization 0.369



Latest news about Fennec Pharmaceuticals Inc.


Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

PDUFA for Pedmark (sodium thiosulfate) in treating platinum chemotherapy-induced cytotoxicity (ear toxicity) in children is scheduled on September 23. The company resolved the issues raised in the second CRL within 3 months and announced the NDA acceptance in April this year.

Date : 22/08/2022

Fennec Pharmaceuticals - Biopharma

100% technical buy signals. 16 new highs and up 22.29% in the last month.

Date : 21/07/2022

Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?

Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.

Date : 23/06/2022

Wall Street Analysts Predict an 80% Upside in Adherex Technologies Inc. (FENC): Here's What You Should Know

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Date : 03/06/2022

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.

Date : 23/05/2022





About Fennec Pharmaceuticals Inc.


CEO : Mr. Rostislav Raykov
Sector : Healthcare
Industry : Biotechnology

Website : https://www.fennecpharma.com

Exchange : NASDAQ Capital Market

Description :

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.


My Newsletter

Sign Up For Updates & Newsletters